Top ten stories in the pharmaceutical industry this week
August 19, 2016Medical Communications pharmafile, top ten
The end of another week, and from huge expansions and investments to some shocking and saddening tragedies, it’s been a …
EU grants marketing authorisation for Teva’s asthma drug Cinqaero
August 19, 2016Medical Communications, Sales and Marketing EU, Teva, approval, asthma, cinqaero, eosinophilic
The European Commission has granted marketing authorisation for Teva’s Cinqaero (reslizumab), as an odd-on therapy in adult patients with severe …
Bayer’s liver cancer drug not cost-effective, says NICE
August 19, 2016Medical Communications, Sales and Marketing Bayer, CDF, NICE, Nexavar, lung cancer
NICE has deemed Bayer’s liver cancer drug Nexavar (sorafenib) as not cost-effective. The drug is currently available on the Cancer …
Former shareholders sue Valeant, alleging “vast fraud”
August 19, 2016Medical Communications, Sales and Marketing Valeant, fraud, lawsuit, t rowe price
Valeant Pharmaceuticals has confirmed that it is being sued by one its former largest shareholders, T Rowe Price, who claim …
Intercept’s Ocaliva meets primary endpoint in Phase III trial for rare liver disease
August 18, 2016Medical Communications, Research and Development intercept, ocaliva
Intercept Pharmaceuticals have announced the publication of Phase III results published in the New England Journal of Medicine, where Ocaliva …
Chinese investors plan $1 billion US biotech site
August 18, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing
China’s state-backed developer Greenland Holdings is set to jointly invested over $1 billion in a San Francisco-based biotech industrial park …
J&J loses Remicade patent fight, pledges to continue fight against biosimilars
August 18, 2016Research and Development, Sales and Marketing Johnson and Johnson, Remicade, biosimilar, biosimilars, infliximab, patent
Johnson and Johnson has announced that it has lost in a patent dispute between biosimilar makers Celltrion and Hospira, relating …
Pfizer’s Xalkori price drop secures NICE recommendation
August 18, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing NICE, Pfizer, Xalkori, crizotinib, lung cancer
The National Institute for Health and Care Excellence (NICE) has recommended Pfizer’s Xalkori (crizotinib) as a treatment for lung cancer, …
MSD joins Medivation race, says reports
August 18, 2016Manufacturing and Production, Research and Development, Sales and Marketing MSD, Medivation, Merck, Pfizer, Sanofi, Xtandi, takeover
MSD, known as Merck in the US and Canada, is said to have declared its interest in buying US oncology …
NICE says Afinitor and Imbruvica “may be removed” from Cancer Drugs Fund
August 18, 2016Research and Development, Sales and Marketing Afinitor, Cancer Drugs Fund, Janssen, NICE, Novartis, imbruvica
NICE has published draft guidance advising the removal of Novartis’s Afinitor (everolimus) and Janssen’s Imbruvica (ibrutinib) from the Cancer Drugs …
Untested cancer drug suspected cause of three deaths at German alternative medicine centre
August 17, 2016Research and Development 3-Bromopyruvate, Cancer, Germany, alternative medicine, patient deaths
The deaths of three patients at an alternative medicine clinic in Germany have prompted suspicion of a clinically untested cancer …
GSK, Roche and Novo back $86 million immuno-oncology startup
August 17, 2016Research and Development CD47, Cancer, GSK, Novo, Roche, Tioma, oncology
Brisbane-based venture-stage biopharmaceutical company Tioma Therapeutics has announced it has raised $86 million in Series A venture financing for its …
Amgen, Sanofi cholesterol medicines “not cost-effective”, need to drop price by two-thirds
August 17, 2016Research and Development, Sales and Marketing Amgen, QALY, Regeneron, Repatha, Sanofi, cost effective, cost-effective, praluent
A new study published in JAMA has suggested that Amgen, Sanofi and Regeneron would have to reduce their prices for …
ViiV Healthcare launches Phase III trial for combo HIV treatment
August 16, 2016Research and Development Dolutegravir, HIV, Tivicay, ViiV Healthcare, epivir, lamivudine, phase III
The Pfizer/GSK spin off ViiV Healthcare has announced the beginning of a Phase III evaluating Tivicay (dolutegravir) and Epivir (lamivudine) …
MSD to cut 148 jobs at Pennsylvania plant
August 16, 2016Manufacturing and Production, Research and Development MSD, job cuts, zontivity
MSD is due to cut 148 jobs at its North Wales, Pennsylvania campus effective September 12, according to the company’s …
Ashfield launches Global Impact On Society Initiative
August 16, 2016Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing
Ashfield, part of UDG Healthcare plc (LON: UDG), a global leader in providing outsourced healthcare services to pharmaceutical, device and …
13 deaths in Aurinia’s lupus drug trial despite hitting Phase II target
August 16, 2016Manufacturing and Production, Research and Development Aurinia, Phase II, biotech, patient deaths, voclosporin
Canadian biotech Aurinia Pharmaceuticals has announced the topline Phase IIb trial results of its lupus nephritis (LN) treatment voclosporin, which …
Vertex stumbles in Phase III cystic fibrosis trials
August 16, 2016Manufacturing and Production, Research and Development Vertex, cystic fibrosis, phase III
Vertex Pharmaceuticals has provided an update on its ongoing Phase III trials investigating VX-661 in combination with Kalydeco (ivacaftor) in …
US court rules in favour of UCB in patent dispute, shares jump
August 16, 2016Manufacturing and Production, Research and Development, Sales and Marketing UCB, lacosamide, patent, vimpat
UCB has received a major boost after a Delaware district court confirmed the validity of the company’s patents on one …
FDA finds drug class at centre of French trial tragedy do not pose similar safety risks
August 15, 2016Manufacturing and Production, Research and Development Bial, Biotrial, FDA, faah, rennes
The US Food and Drug Administration (FDA) has issued a statement following the results of their investigation into the recent …
Latest content
One in three UK women with migraine say symptoms taken less seriously
Report highlights scope to expand day surgery
Sygnature formalises drug discovery collaboration with X-Chem
Codis appoints Steven Facer as chief commercial officer
Danish medical cannabis use rises as regulator reports no new safety signals
